P.2 9



### ATSDK - Minima l Ris k Level s fo r Hazardou s Substance s (MRLs ) 

# ATSD R

AGENC Y FO R TOXI C SUBSTANCE S AN O DISEAS E REGISTR Y RELATE D RESOURCE S PD F fo rPrintin g (37k

) CONTENTS Narrativ e MR L Lis t ATSD R RESOURCE S Divisio n o f Toxicolog y Toxicologica l Profile s 

### Pag e 1 of .1 1 Docke t No
. A-79-1 5 ItemNo.XlI-I-5 0 Searc h | Inde

x | Hom e | Glossar

y | Contac t U s 

# Minima l Ris k

Level s (MRLs ) fo r Hazardou s Substance s

The Comprehensiv e Environmenta l Response , Compensation , an d Liabilit y Act (CERCLA) [4 2 U.S.C
. 9604 et seq.] , a s amende db y th e Superfun dAmendment s an dReauthorizatio n Ac t (SARA ) [Pub
. L
. 99

- 499] , require s tha

t th e Agenc y fo

r Toxi c Substance s an dDiseas e Registr y (ATSDR

) develop jointl y wit

h th e U.S
. Environmenta

l Protectio n Agency (EPA) , i n orde r o f priority , alis t

of hazardou s substance s mos t

commonly foun

da t facilitie s on th e CERCL

A Nationa l Prioritie s Lis t

(NPL ) (4 2 U.S.C
. 9604(i)(2)) ; prepare toxicologica l profile s fo r eac h substanc e include don th e priorit y lis t of hazardou s substances , an

dt o ascertai n significan

t huma n exposure level s (SHELs ) fo r hazardou s substance s i n th e environment , an dth e associate dacute , subacute , an

dchroni c healt

h effect s (4 2 U.S.C
. 9604(i)(3)) ; andassur e the initiatio n o

f aresearc h progra

mt o fill identifie ddat aneed s associate dwit

h th e substance s (4 2 U.S.C
. 9604(i)(5))
. The ATSDRMinima

l Ris k Level s (MRLs ) wer

e develope da s a

n initia l respons e t o th e mandate
. Followin g discussion s wit h scientist s withi n th e Departmen

t o f Healt h andHuma

n Service s (HHS ) andth e EPA , ATSD Rchos e to adop t

apractic e simila

r to tha t o f th e EPA' s Referenc e Dos e (RfD ) an

dReferenc e Concentratio n (RfC ) for derivin g substance

specific healt

h guidanc e level s fo

r non-neoplasti c endpoints
. A n MR L i s a n estimat e o f th e dail y huma

n exposur e to ahazardou s substanc e tha t i s likely t o b e without

appreciabl e risk

of advers e noncancer

healt h effect s ove r aspecifiedduratio n o

f exposure . Thes e substance-specifi c estimates , whic

h ar e intende dto serv e a s screenin g levels , ar e use db y ATSD Rhealt h assessor s andother

responder s t o identif

y contaminant s an dpotentia l healt h effect s tha

t ma y b e of concema t hazardou s waste sites
. I ti s importantt o note tha tMRL s are no tintende d to define clean-up o ractio n level s fo rATSD Ro rothe rAgencies . The toxicologica

l profile s includ e a

n examination , summary , and interpretatio n o

f availabl e toxicologica

l informatio n andepidemiologi c evaluation s o

f ahazardou s substance
. Durin g th e development o f toxicologica

l profiles , MRL s ar

e derive dwhe

n ATSD Rdetermine s tha

t reliabl e andsufficien

t dat aexis t t o identif y th e targe t

organ(s ) o

f effec t or th e mos t sensitiv e healt

h effect(s ) fo

r aspecifi c duratio n fo

r agiven rout e o f exposur e to th e substance
. MRL s ar e base don noncance

r healt h http://www.atsdr.cdc.gov/mrls.htm l 7/10/200 3P.3 0



### ATSD R- Minima

l Ris k Level s fo r Hazardou s Substance s (MRLs ) Pag e 2 of 1 1
effects onl y an dar e not base do n aconsideratio n o

f cancer effects
. Inhalatio n MRL s ar

e exposur e concentration s expresse di n unit s of part s per millio n (ppm

) fo r gase s an dvolatiles , or

milligram s per

cubi c meter (mg/m3 ) fo

r particles
. Ora

l MRL s ar e expresse da s daily huma

n dose s i n unit s o f milligram s pe

r kilogra mpe r da y (mg/kg/day)
. Radiatio n MRL s ar e expresse da s externa

l exposure s in unit s o

f millisieverts
. ATSDRuse s the no-observed-adverse-effect-level/uncertaint y factor (NOAEL/UF) approach to deriv e MRL s fo r hazardou s substances
. They ar e set belo w level s that , base do

n current information , migh

t caus e advers e healdi effects in th e peopl e mos t sensitiv e t o suc h substance

induce deffects
. MRL s ar

e derive dfo

r acut e (1-1 4 days) , intermediate (>14-364 days) , an

dchroni c (36 5 day s an dlonger) exposur e durations , an dfo r the ora l an dinhalatio n route s of

exposure . Currently MRL s fo r th e derma l route o f exposur e ar e not derive dbecaus e ATSDRha s no t ye t identifie dametho dsuitabl e fo r thi s route of

exposure . MRL s ar

e generally base do

n th e mos t sensitiv e substance-induce dendpoin t considere dt o b e o

f relevanc e to humans
. ATSD Rdoe s no t us e seriou s healt h effects (such a s irreparabl e damag e t o th e liver o r kidneys , o r birt h defects ) a s abasi s fo

r establishin g MRLs
. Exposure t o aleve l abov e th e MR

L doe s no t mea n tha t advers e healt

h effect s wil l occur . MRL s ar e intende dto serv e a s ascreenin g too l to hel p publi c healt h professional s decide wher

e to look mor e closely
. The y ma

y als o b e viewe da s amechanis mt o identif y thos e hazardou s waste site s tha t are no t expecte dt o caus e advers e healt h effects
. Mos t

MRL s contai n some degre e o f uncertaint y becaus e o

f th e lac k of precis e toxicologica

l informatio n o

n th e peopl e wh o migh

t b e mos t sensitiv e (e.g. , infants , elderly , an dnutritionally o r immunologically compromised ) t o effect s o f hazardou s substances
. ATSD Ruse s aconservativ e (i.e. , protective ) approach t o addres s thes e uncertaintie s consistent wit h th e publi c healt

h principl e o

f prevention
. Althoug h huma n dataar e preferred , MRL s ofte

n mus t b e base do

n anima l studie s becaus e relevant

huma n studie s are lacking
. In th e absenc e o

f evidenc e t o th e contrary , ATSD Rassume s tha t human s ar e mor e sensitiv e tha

n animal s to th e effect s o

f hazardou s substance s tha

t certain person s ma

y b e particularl y sensitive
. Thu s th e resultin g MR

L ma y b e a s much a s ahundredfol dbelo w level s shown t o b e nontoxi c in laborator

y animals
. Whe

n adequate informatio n i s available , physiologicall y base dpharmacokineti c (PBPK) modelin g an d benchmar k dos e (BMD ) modelin g hav e als o been use da s a n adjunc t t o th e NOAEL/UFapproac h i n derivin g MRLs
. Propose dMRL s underg o arigorous revie w process . The y ar e reviewe d b y th e Healt

h Effects/MR

L Workgroup withi n th e Divisio n of Toxicology ; an dexper

t pane l o f externa l peer reviewers ; th e agenc y wide MR L Workgroup , wit

h participatio n fro

mother federa l agencies , includin g EPA ; andar

e submitte dfor

publi c comment

through th e toxicologica

l profil e publi c commen

t period
. Eac h MR

L i s subject

t o chang e as new informatio n become s availabl e concomitant witii updatin g th e toxicologica

l profil e o f th e substance
. MRL s in th e mos t recent toxicologica

l profile s supersede previousl y publishe dlevels
. T o http://www.atsdr.cdc.gov/mrls.htm l 7/10/200 3P.3 1



### ATSD R- Minima

l Ris k Level s fo r Hazardou s Substance s (MRLs ) Pag e 3 o f 1 1
date , 12 0 inhalatio n MRLs , 189 ora l MRL s an d6 extema

l radiatio n MRL s have bee

n derived
. A listin g o

f th e curren t publishe dMRL s b y route an dduratio n o

f exposur e i s provide da s follows
. ATSD RContac

tPerso n fo rMRLs : Dr
. Selene Cho

u Divisio n o f Toxicolog y Agency fo r Toxi c Substance s an

dDiseas e Registr

y 160 0 Clifton Road , Mailsto p E2 9 Atlanta , Georgi a3033 3 Telephone : 404-498-070 5 E-Mail : cjc3@cdc.go v Note : Informatio n i s i n landscap e format. Pleas e us e scrol l baro n th e botto m ofth e scree n to acces s all th e information . You ca n als o searc

h th e index of

substance s quickly b y usin g th e "Find " butto n o n you rwe b browser . Fo rprintouts , pleas e us e th e PD F format . Th e PD F formatrequire s Adob e AcrobatReader , which can b e downloaded fre e from th e Adob e **"> we b site .

Name ATSD R MINIMA

L RIS K LEVEL S (HRLs ) Januar y 200 3

Rout e
Ora l Inh .
Ora l Inh . Ora l Inh . Ora l

Ora l

Ora l Inh . Ora l Ora l Dura tio n

Int . Acut e Int . Oir . Int . Acut e Int . Chr . Acut e Acut e Int . Chr . Acut e Chr . Int . Acut e Chr . Int . Int . MR L

0. 6 mg/kg/day 2 6 pp m 1 3 pp m 1 3 pp m 2 mg/kg/day 0.0000 5 pp

m 0.00000 9 pp

m 0.000 5 mg/kg/day 0. 1 pp m 0. 1 mg/kg/day 0.0 1 mg/kg/da y 0.0 4 mg/kg/da y 0.00 2 mg/kg/da y 0.0000 3 mg/kg/da y 2. 0 mg/kg/da y 1. 7 pp m 0. 3 pp m 0. 3 mg/kg/da y 1 0 mg/kg/da y Fac tor s
30 0 9 10 0 10 0 10 0 10 0 100 0 10 0 1 0 10 0 100 0 10 0 100 0 100 0 3 0 3 0 1 0 10 0 10 0 Endpoin t Hepati c Neurol . Neurol . Neurol . Hemato . Ocula r Resp . Hemato . Neurol . Develop . Repro . Hemato . Develop . Hepati c Neurol . Resp . Resp . Othe r Hepati c ACENAPHTHEN E ACETON E

ACROLEI N

ACRYLONITRIL E

ALDRI N

ALUMINU M AMMONI A

ANTHRACEN E


### http://www.atsdr.cdc.gov/mrls.htm l 7/10/200 3P.3 2



### ATSD R- Minima

l Ris k Level s for

Hazardou s Substance s (MRLs ) Pag e 4 o f 1 1

ARSENI C

ATRAZINE BENZENE

BERYLLIU

M BIOALLETHRI N BIS(CHLOROMETHYL ) ETHE R BIS(2-CHLOROETHYL ) ETHE R BORON BROMODICHLOROMETHANE

BROMOFOR

M
BROMOMETHANE

CADMIU M CARBO N DISULFID E
CARBO N TETRACHLORID

E

CESIU M
CHLORDAN

E

CHLORDECON

E

CHLORFENVINPHO S

CHLORINE DIOXID E Provisiona l Ora l
Ora l Inh .
Ora l Ora l Inh . Inh . Ora l Ora l

Ora l
Inh .
Ora l Ora l Inh . Ora l inh . Ora l
Rad .
Inh . Ora l

Ora l

Ora l

inh . Acut e 0.00 5 mg/kg/day Chr . 0.000 3 mg/kg/day Acut e 0.0 1 mg/kg/day 1 0 3 Gastro . Derma l 10 0 Bod

y Wt . Acut e Int . Chr . Acut e Int . Int . int . Acut e Chr . Acut e Chr . Acut e Int . Chr . Int . Chr . Chr . Acut e Acut e int . Acut e int . Acut e Chr . Int . Chr . Acut e Int . Chr . Acut e Int . Chr . Acut e Int . Chr . Int . 0.0 5 pp

m 0.00 4 pp

m 0.00 2 mg/kg/day 0.000 7 mg/kg/day 0.000 3 pp

m 0.0 2 pp m 0.0 1 mg/kg/day 0.0 4 mg/kg/day 0.0 2 mg/kg/day 0. 6 mg/kg/day 0. 2 mg/kg/day 0.0 5 pp m 0.0 5 pp m 0.00 5 pp

m 0.00 3 mg/kg/day 0.000 2 mg/kg/day 0. 3 pp m 0.0 1 mg/kg/day 0. 2 pp m 0.0 5 pp m 0.0 2 mg/kg/day 0.00 7 mg/kg/day 4 mS v 1 mSv/yr 0.000 2 mg/m 3 0.0000 2 mg/m 3 0.00 1 mg/kg/day 0.000 6 mg/kg/day 0.000 6 mg/kg/da y 0.0 1 mg/kg/da y 0.000 5 mg/kg/da y 0.000 5 mg/kg/da y 0.00 2 mg/kg/day 0.00 2 mg/kg/da y 0.000 7 mg/kg/day 0.00 1 pp

m 30 0

9 0 30 0 30 0 10 0 100 0 100 0 100 0 100 0 10 0 10 0 10 0 10 0 10 0 10 0 Tiiimiino . Neurol . Gastro . Develop . Resp . Bod y Wt . Develop . Hepati c Rena l Neurol . Hepati c Neurol . Neurol . Neurol . Gastro . 1 0 Rena l 3 0 30 0 30 0 10 0 30 0 10 0 3 3 10 0 100 0 100 0 10 0 10 0 10 0 10 0 10 0 100 0 100 0 100 0 Neurol . Hepati c Hepati c Hepati c Hepati c Hepati c Develop . Othe r Hepati c Hepati c Develop . Hepati c Hepati c Neurol . Rena l Rena l Neurol . •Tnnwuno . Neurol . 30 0 Resp .


### http://www.atsdr.cdc.gov/mrls.htm l 7/10/200 3

### ATSD R - Minima l Ris k Level s fo r Hazardou s Substance s (MRLs ) Pag e 5 o f 1 1

CHLORIT E Ora l Int . 0. 1 mg/kg/day 3 0 Neuro l

CHLOROBENZEN E CHLOR0DIBROMOMETHANE

CHLOROETHANE CHLOROFOR

M Ora l Int . 0. 4 mg/kg/day 10 0 Hepati c

CHLOROMETHANE

CHLORPYRIFO S

CKROMIUM(VI) , AEROSO L MIST S CHROMIUM(VI) , PARTICULATE S COBAL T

COPPE R

CRESOL , META CRESOL , ORTHO CRESOL , PARA CYANIDE , SODIU

M Ora l Acut e 0.0 4 mg/kg/day Chr . 0.0 3 mg/kg/day Inh . Acut e 1 5 pp

m

Ora l Acut e 0.0 2 mg/kg/da y
Ora l Acut e 0.0 5 mg/kg/da y Ora l Acut e 0.0 5 mg/kg/da y Ora l Acut e 0.0 5 mg/kg/da y Ora l int . 0.0 5 mg/kg/da y CYCLOTBTRAMETHYLEN E TETRANITRAMIN

E Ora l Acut e 0. 1 mg/kg/da y (HMX ) Int . 0.0 5 mg/kg/da y CYCLOTRIHETHYLENETRINITRAMINE (RDX ) Ora l Acut e 0.0 6 mg/kg/da y Int . 0.0 3 mg/kg/da y DDT , P,P' -
DEX.TAMETHRI

N DI(2-ETHYLHEXYL)PHTHALAT E

DI-N-BUTY L PHTHALAT E Ora l Acut e 0.000 5 mg/kg/da y Int . 0.000 5 mg/kg/da y Ora l Acut e 0.00 2 mg/kg/da y Ora l Int . 0. 1 mg/kg/da y Chr . 0.0 6 mg/kg/da y Ora l Acut e 0. 5 mg/kg/da y 100 0 100 0 Rena l Hepati c

Inh .
Ora l

Inh .

Ora l

Inh . inh . Inh . Ora l Rad . Acut e Int . Chr . Acut e Int . Chr . Acut e int . Chr . Acut e Int . Chr . Int . Int . Chr . Int . Acut e Chr . 0. 1 pp

m 0.0 5 pp m 0.0 2 pp m 0. 3 mg/kg/day 0. 1 mg/kg/day 0.0 1 mg/kg/day 0. 5 pp m 0. 2 pp m 0.0 5 pp m 0.00 3 mg/kg/day 0.00 3 mg/kg/day 0.00 1 mg/kg/day 0.00000 5 mg/m 3 0.00 1 mg/m 3 0.000 1 mg/m 3 0.0 1 mg/kg/da y 4 mS v 1 mSv/y r 3 0 10 0 10 0 10 0 10 0 100 0 10 0 30 0 100 0 1 0 1 0 10 0 10 0 3 0 1 0 10 0 3 3 10 0 Develop . Hepati c Hepati c Hepati c Hepati c Hepati c Hepati c Neurol . Hepati c Neurol . Neurol . Neurol . Neurol . Resp . Resp . Resp . Hemato . Develop . Othe r Gastr o Int . Resp . Neurol . Neurol . Repro . Neurol . Hepati c Neurol . Repro . Develop . Hepati c 10 0 10 0 10 0 10 0 100 0 100 0 10 0 30 0 100 0 10 0 30 0 Develop . 10 0 10 0 Repro . Repro . 10 0 Develop . 

### http://www.atsdr.cdc.gov/mrls.htm l 7/10/200 3P.3 4



### ATSD R - Minima l Ris k Level s fo r Hazardou s Substance s (MRLs )

DI-N-OCTY L PHTHALAT E

DIAZINO N

DICHLORVO S

DIELDRI N

DIETHY L PHTHALAT E

DIISOPROPY L METHYLPHOSPHONAT E (DIMP ) DISULFOTO

N

ENDOSULFA

N

ENDRI N

ETHION

ETHYLBENZENE ETHYLENE GLYCO L

ETHYLEN E OXID E FLUORANTHEN

E FLUOREN E FLUORIDE , SODIU

M FLUORIN E FORMALDEHYD E Ora l
Inh . Ora l Inh .
Ora l

Ora l

Ora l

Ora l
Inh . Ora l

Ora l

Ora l

Ora l

inh . Inh . Ora l
Inh . Ora l Ora l Ora l Inh . Inh .
Ora l Acut e Int . Int . Int . Acut e Int . Chr . Acut e Int . Chr . Int . Chr . Acut e Int . Int . Chr . Acut e Int . Acut e Int . Chr . Int . Chr . int . Chr . Acut e Int . Chr . Int . Acut e Acut e Chr . Int . Int . Int . Chr . Acut e Acut e Int . Chr . Int . Chr . 3 mg/kg/day

0. 4 mg/kg/day 0.00 9 mg/m 3 0.000 2 mg/kg/day 0.00 2 pp

m 0.000 3 pp

m 0.0000 6 pp

m 0.00 4 mg/kg/day 0.00 3 mg/kg/day 0.000 5 mg/kg/day 0.000 1 mg/kg/day 0.0000 5 mg/kg/day 7 mg/kg/day 6 mg/kg/day 0. 8 mg/kg/day 0. 6 mg/kg/day 0.00 6 mg/m 3 0.000 2 mg/m 3 0.00 1 mg/kg/day 0.0000 9 mg/kg/da y 0.0000 6 mg/kg/da y 0.00 5 mg/kg/da y 0.00 2 mg/kg/da y 0.00 2 mg/kg/da y 0.000 3 mg/kg/da y 0.00 2 mg/kg/da y 0.00 2 mg/kg/da y 0.000 4 mg/kg/da y 1. 0 pp m 0. 5 pp m 2. 0 mg/kg/da y 2. 0 mg/kg/da y 0.0 9 pp m 0. 4 mg/kg/da y 0. 4 mg/kg/da y 0.0 6 mg/kg/da y 0.0 1 pp m 0.0 4 pp m 0.0 3 pp m 0.00 8 pp

m 0. 3 mg/kg/da y 0. 2 mg/kg/da y 30 0 10 0 3 0 10 0 10 0 10 0 10 0 100 0 1 0 10 0 10 0 10 0 30 0 30 0 10 0 10 0 3 0 3 0 10 0 10 0 100 0 10 0 10 0 10 0 10 0 3 0 3 0 15 0 10 0 10 0 10 0 10 0 10 0 30 0 30 0 1 0 1 0 9 3 0 3 0 10 0 10 0 

### Pag e 6 o f 1 1

Hepati c Hepati c Neurol . Neurol . Neurol . Neurol . Neurol . Neurol . Neurol . Neurol . Neurol . Hepati c Repro . Hepati c Hemato . Hemato . Neurol . Neurol . Neurol . Develop . Neurol . Xmxmino . Hepati c Neurol . Neurol . Neurol . Neurol . Neurol . Develop . Rena l Develop . Rena l Rena l Hepati c Hepati c Musculo . Resp . Resp . Resp . Resp . Gastro . Gastro . 

### http://www.atsdr.cdc.gov/mrls.htm l 7/10/200 3P.3 5



### ATSD R- Minimal Ris k

Level s fo r Hazardou s Substance s (MRLs ) Pag e 7 of 1 1

FUE L OI L NO . 2 HEXACHLOROBENZEN E

HEXACHLOROBUTADIEN E HEXACHLOROCYCLOHEXANE , ALPHA HEXACHLOROCYCLOKEXANE , BETA KEXACHLOROCYCLOPENTADIENE

HEXACHLOROCYCLOHEXANE , GAMMA HEXACHLOROETHAN E

HEXAMETHYLENE DIISOCYANAT E

HEXANE , N HYDRAZIN E HYDROGEN

FLUORID E

HYDROGEN

SULFID E

IODID E

IONIZIN G RADIATION , N.O.S .
ISOPHORONE

JP- 4 JP-5/JP- 8 JP- 7 KEROSEN E MALATHIO

N Inh . Ora l

Ora l Ora l Ora l
Inh . Ora l Ora l
Inh . Ora l
Inh .
Inh . Inh . Inh .
Inh .
Ora l
Rad .
Ora l
Inh . Inh . Inh . Inh . Inh . Ora l Acut e Acut e Int . Chr . Int . Chr . Acut e Int . Int . Chr . Int . Acut e Int . Acut e Int . Acut e Int . Int . Chr . Chr . Int . Acut e Int . Acut e Int . Acut e Chr . Acut e Chr . Int . Chr . Int . Int . Chr . Int . Acut e Int . Int . Chr . 0.0 2 mg/m 3

0.00 8 mg/kg/day 0.000 1 mg/kg/day 0.0000 5 mg/kg/day 0.000 2 mg/kg/day 0.00 8 mg/kg/day 0. 2 mg/kg/day 0.000 6 mg/kg/day 0.0 1 pp m 0.000 2 pp

m 0. 1 mg/kg/day 0.0 1 mg/kg/day 0.0000 1 mg/kg/day 6 pp m 6 pp m 1 mg/kg/day 0.0 1 mg/kg/day 0.0000 3 pp

m 0.0000 1 pp

m 0. 6 pp m 0.00 4 pp

m 0.0 3 pp m 0.0 2 pp m 0.0 7 pp m 0.0 3 pp m 0.0 1 mg/kg/da y 0.0 1 mg/kg/da y 4 mS v 1 mSv/y r 3 mg/kg/da y 0. 2 mg/kg/da y 9 mg/m 3 3 mg/m 3 0. 3 mg/m 3 0.0 1 mg/m 3 0. 2 mg/m 3 0.0 2 mg/m 3 0.0 2 mg/kg/da y 0.0 2 mg/kg/da y 100 0 30 0 9 0 30 0 100 0 10 0 10 0 30 0 3 0 9 0 10 0 10 0 100 0 3 0 3 0 10 0 10 0 3 0 9 0 10 0 30 0 3 0 3 0 3 0 3 0 1 1 3 3 10 0 100 0 30 0 30 0 30 0 100 0 10 0 100 0 1 0 10 0 Neurol . Develo p Repro . Develo p Rena l Hepati c Neurol . Hepati c Resp . Resp . Rena l Neurol . Xmmuno . Neurol . Neurol . Hepati c Hepati c Resp . Resp . Neurol . Hepati c Resp . Resp . Resp . Resp . Endocr . Endocr . Neurol . Othe r Othe r Hepati c Hepati c Hepati c Hepati c Hepati c Neurol . Resp . Neurol . Neurol . 

### http://www.atsdr.cdc.gov/mrls.htm l 7/10/200 3

### ATSD R- Minima l Ris k Level s fo r Hazardou s Substance s (MRLs ) Pag e 8 o f 1 1

MANGANES E MERCURI C CHLORID E
MERCUR Y METHOXYCHLOR METHY L PARATHIO

N

METHYL-T-BUTY L ETHE R

METHYLEN E CHLORID E

METHYLMERCUR

Y MIRE X MUSTAR D GA S

N-NITROSODI-N-PROPYLAMINE NAPHTHALENE

NICKE L PENTACHLOROPHENO L

PHOSPHORUS , WHIT E

POLYBROMINATE D BIPHENYL S (PBBs ) POLYBROHINATE D DIPHENY L ETHER S

POLYCHLORINATE D BIPHENYL S (PCBs ) Aroclo r 125 4 PROPYLEN E GLYCO L DINITRAT E Inh . Ora l
Inh . Ora l Ora l
Inh .
Ora l
Inh .
Ora l
Ora l Ora l Inh . Ora l

Ora l Inh . Ora l
Inh . Ora l

Inh . Ora l Ora l Ora l

Ora l
Inh . Chr . Acut e Int . Chr . Int . Int . Chr . Acut e Int . Chr . Acut e Int . Acut e Int . Chr . Acut e Chr . Chr . Chr . Acut e Acut e Int . Acut e Chr . Acut e Int . Chr . Acut e Int . Chr . Acut e Int . Acut e Acut e int . Int . Chr . Acut e Int . Chr . 0.0000 4 mg/m 3

0.00 7 mg/kg/day 0.00 2 mg/kg/day 0.000 2 mg/m 3 0.00 5 mg/kg/day 0.000 7 mg/kg/day 0.000 3 mg/kg/day 2 pp m 0. 7 pp m 0. 7 pp m 0. 4 mg/kg/day 0. 3 mg/kg/day 0. 6 pp m 0. 3 pp m 0. 3 pp m 0. 2 mg/kg/day 0.0 6 mg/kg/day 0.000 3 mg/kg/day 0.000 8 mg/kg/da y 0.000 2 mg/m 3 0. 5 ug/kg/day 0.0 2 ug/kg/day 0.09 5 mg/kg/da y 0.00 2 pp

m 0.0 5 mg/kg/da y 0.0 2 mg/kg/da y 0.000 2 mg/m 3 0.00 5 mg/kg/da y 0.00 1 mg/kg/da y 0.00 1 mg/kg/da y 0.0 2 mg/m 3 0.000 2 mg/kg/da y 0.0 1 mg/kg/da y 0.0 3 mg/kg/da y 0.00 7 mg/kg/da y 0.0 3 ug/kg/da y 0.0 2 ug/kg/da y 0.00 3 pp

m 0.0000 4 pp

m 0.0000 4 pp

m 50 0

10 0 10 0 3 0 100 0 30 0 10 0 10 0 10 0 10 0 10 0 30 0 10 0 9 0 3 0 10 0 10 0 4 10 0 90 0 100 0 100 0 10 0 100 0 100 0 30 0 3 0 100 0 100 0 100 0 3 0 10 0 10 0 3 0 30 0 30 0 30 0 1 0 100 0 100 0 Neurol . Rena l Rena l Neurol . Repro . Neurol . Hemato . Neurol . Neurol . Rena l Neurol . Hepati c Neurol . Hepati c Hepati c Neurol . Hepati c Develop Hepati c Resp . Develop Gastro . Hepati c Resp . Neurol . Hepati c Resp . Develop Repro . Endocr . Resp . Repro . Endocr . Endocr . Hepati c Neurol . Immuno . Neurol . Hemato . Hemato .


### http://www.atsdr.cdc.gov/mrls.htm l 7/10/200 3PROPYLEN E GLYCO L

REFRACTOR

Y CERAMI C FIBER S SELENIU M STRONTIU

M STYREN E

SULFU R DIOXID E TETRACHLOROETHYLENE

TITANIU M TETRACHLORID E

TOLUEN E

TOXAPHENE
TRICHLOROETHYLENE

URANIUM , HIGHL Y SOLUBL E SALT S

URANIUM , INSOLUBL E COMPOUND S VANADIU M

VINY L ACETAT E VINY L CHLORID E

XYLENE , M XYLENE , P XYLENES , TOTA

L

ZINC

1 -METHYLNAPHTHALEN E 

### http://www.atsdr.cdc.gov/mrls.htm l u s Su b

Inh . Inh . Ora l Ora l Inh . Ora l Inh . Inh . Ora l Inh .
Inh . Ora l

Ora l
Inh . Ora l Inh . Ora l Inh . Inh . Ora l Inh . Inh . Ora l Ora l Ora l Inh .
Ora l Ora l

Ora l 

### stance s (

Int . Chr . Chr . Int . Chr . Int . Acut e Acut e Chr . Acut e Int . Chr . Acut e Chr . Acut e int . Acut e int . Acut e Int . Acut e Int . Chr . Int . Int . Acut e Int . Int . Acut e Int . Chr . Int . Acut e Acut e Int . Chr . int . Int . Chr . Chr . 

### MRLs )

0.00 9 pp

m 0.0 3 fibers/c c 0.00 5 mg/kg/day 2 mg/kg/day 0.0 6 pp m 0. 2 mg/kg/day 0.0 1 pp m 0. 2 pp m 0.0 4 pp m 0.0 5 mg/kg/day 0.0 1 mg/m 3 0.000 1 mg/m 3 1 pp m 0.0 8 pp m 0. 8 mg/kg/day 0.0 2 mg/kg/day 0.00 5 mg/kg/day 0.00 1 mg/kg/day 2 pp m 0. 1 pp m 0. 2 mg/kg/day 0.000 4 mg/m 3 0.000 3 mg/m 3 0.00 2 mg/kg/day 0.00 8 mg/m 3 0.000 2 mg/m 3 0.00 3 mg/kg/da y 0.0 1 pp m 0. 5 pp m 0.0 3 pp m 0.0000 2 mg/kg/da y 0. 6 mg/kg/da y 1 mg/kg/da y 1 pp m 0. 7 pp m 0. 1 pp m 0. 2 mg/kg/da y 0. 3 mg/kg/da y 0. 3 mg/kg/da y 0.0 7 mg/kg/da y 

### Pag e 9 o f 1 1

100 0 Resp . 3 0 Resp . 3 Derma l 3 0 Musculo . 10 0 Neurol . 100 0 Hepati c 9 Resp . 1 0 Neurol . 10 0 Neurol . 10 0 Develop . 9 0 Resp . 9 0 Resp . 1 0 Neurol . 10 0 Neurol . 30 0 Neurol . 30 0 Neurol._

_ 100 0 Hepati c 30 0 Hepati c 3 0 Neurol . 30 0 Neurol . 30 0 Develop . 9 0 Rena l 3 0 Rena l 3 0 Rena l 3 0 Rena l 10 0 Resp . 10 0 Rena l 10 0 Resp . 10 0 Develop . 30 0 Hepati c 100 0 Hepati c 100 0 Hepati c 10 0 Neurol . 10 0 Neurol . 30 0 Develop . 10 0 Neurol . 100 0 Rena l 3 Hemato . 3 Hemato . 100 0 Resp .


### 7/10/200 3P.3 8



### ATSD R- Minimal Ris k

Level s fo r Hazardou s Substance s (MRLs )

1,l-DICHLOROETHEN E
1,1-DIMETHYLHYDRAZINE 1,1,1-TRICHLOROETHANE
1,1,2-TRICHLOROETHANE
1,1,2,2-TETRACHLOROETHANE

1,2-DIBROMO-3-CHLOROPROPANE
1,2-DICHLOROETHENE , CIS 1,2-DICHLOROETHANE
1,2-DICHLOROPROPANE 

### Pag e 1 0 o f 1 1 

# 1

1,2-DICHLOROETHENE , TRAN S -

1,2-DIMETHYLHYDRAZIN E 1,2,3-TRICKLOROPROPAN E
1,3-DICHLOROPROPEN E
1 , 3-DINITROBENZEN

E
1,4-DICHLOROBENZEN E

2-BUTOXYETHANO L

2,3,4,7,8-PENTACHLORODIBENZOFURA N Inh . Ora l Inh . Inh .
Ora l
Inh . Ora l
Inh . Ora l Ora l
Inh . Ora l Inh . Ora l

inh . Ora l Ora l Inh . Ora l Inh .
Ora l
Inh .
Ora l Inh .
Ora l

Ora l int . Chr . Int . Acut e Int . Acut e Int . Int . Int . Chr . int . Int . Acut e Int . Chr . Int . Acut e Int . Acut e Int . Chr . Acut e Int . Int . Int . Acut e Int . Int . Chr . Acut e Int . Acut e Int . Chr . Int . Acut e Int . Chr . Acut e Int . Acut e Int . 0.0 2 pp

m 0.00 9 mg/kg/da

y 0.000 2 pp

m 2 pp m 0. 7 pp m 0. 3 mg/kg/day 0.0 4 mg/kg/day 0. 4 pp m 0. 6 mg/kg/day 0.0 4 mg/kg/day 0.000 2 pp

m 0.00 2 mg/kg/day 1 mg/kg/day 0. 3 mg/kg/day 0. 6 pp m 0. 2 mg/kg/day 0.0 5 pp m 0.00 7 pp

m 0. 1 mg/kg/day 0.0 7 mg/kg/day 0.0 9 mg/kg/day 0. 2 pp m 0. 2 pp m 0. 2 mg/kg/da y 0.000 8 mg/kg/day 0.000 3 pp

m 0.0 6 mg/kg/da y 0.00 3 pp

m 0.00 2 pp

m 0.00 8 mg/kg/da y 0.000 5 mg/kg/da y 0. 8 pp m 0. 2 pp m 0. 1 ppm 0. 4 mg/kg/da y 6 pp m 3 pp m 0. 2 pp m 0. 4 mg/kg/da y 0.0 7 mg/kg/da y 0.00 1 ug/kg/da y 0.0000 3 ug/kg/da y 10 0 100 0 30 0 10 0 10 0 10 0 10 0 30 0 10 0 100 0 10 0 100 0 10 0 10 0 9 0 30 0 100 0 100 0 100 0 100 0 100 0 100 0 100 0 10 0 100 0 10 0 10 0 10 0 10 0 10 0 100 0 10 0 10 0 10 0 30 0 9 9 3 9 0 100 0 300 0 300 0 Hepati c Hepati c Hepati c Neurol . Neurol . Neurol . Hepati c Hepati c Bod y Wt . Resp . Repro . Repro . Hemato . Hemato . Hepati c Rena l Resp . Resp . Neurol . Hemato . Hepati c Hepati c Hepati c Hepati c Hepati c Resp . Hepati c Resp . Resp . Repro . Hemato . Develo p Hepati c Hepati c Hepati c Hemato . Hemato . Hemato . Hemato . Hepati c Immun e Hepati c


### http://www.atsdr.cdc.gov/mrls.htm l 7/10/200 3

### ^TSD R- Minima l Ris k Level s fo r Hazardou s Substance s (MRLs ) Page1 1 of 1 1
2,3,7,8-TETRACHLORODIBENZO-P-DIOXI N Ora l

2,4-DICHLOROPKENO L 2,4-DINITROPHENO L 2,4-DINITROTOLUENE
2,4,6-TRINITROTOLUENE 2,6-DINITROTOLUENE 4-CHLOROPHENO L Ora l Ora l Ora l

Ora l Ora l Ora l 4,4'-METHYLENEBIS(2-CHLOROANILINE ) Ora l 4,4'-METHYLENEDIANILINE Ora l
4 , 6-DINITRO-O-CRESOL Ora l Acut e 0.000 2 ug/kg/day Int . 0.0000 2 ug/kg/day Chr . 0.00000 1 ug/kg/day Int . 0.00 3 mg/kg/day Acut e 0.0 1 mg/kg/day Acut e 0.0 5 mg/kg/day Chr . 0.00 2 mg/kg/day Int . 0.000 5 mg/kg/day Int . 0.00 4 mg/kg/day Acut e 0.0 1 mg/kg/day Chr . 0.00 3 mg/kg/da y Acut e 0. 2 mg/kg/da y Int . 0.0 8 mg/kg/day Acut e 0.00 4 mg/kg/da y Int . 0.00 4 mg/kg/day 2 1 Timmmo . 3 0 Lymphor . 9 0 Develop . 10 0 Hmnuno . 10 0 Bod y Wt . 10 0 Neurol . 10 0 Hemato . 100 0 Hepati c 100 0 Hemato . 10 0 Hepati c 300 0 Hepati c 30 0 Hepati c 10 0 Hepati c 10 0 Neurol . 10 0 Neurol . Tota l numbe r o f MRLs : 31 5



### Thi s documen t last update d o n Januar y23 , 200 3 Dr . Selen e Cho u / CJC3@cdc.go v

ATSD R Hom e | Searc h | Inde x | Glossar

y | Contac t U s About ATSD R | New s Archive | ToxFAQ s | HazDa t | Publi c Healt h Assasstnant s

Privacy Polic

y | Externa l Link

s Disclaime r | Accessibilit y U.S . Departmen t o

t Healt h an d Huma n Service s



### http://www.atsdr.cdc.gov/mrls.htm l 7/10/200 3